Skye Bioscience Stock Price, News & Analysis (OTCMKTS:SKYE) $1.73 +0.12 (+7.45%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$1.44▼$2.0150-Day Range$1.44▼$4.0952-Week Range$1.44▼$14.00Volume10,680 shsAverage Volume6,136 shsMarket Capitalization$6.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest About Skye Bioscience Stock (OTCMKTS:SKYE)Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Read More SKYE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SKYE Stock News HeadlinesNovember 24, 2023 | americanbankingnews.comFinancial Survey: Skye Bioscience (OTCMKTS:SKYE) and Elite Pharmaceuticals (OTCMKTS:ELTP)November 21, 2023 | finance.yahoo.comSkye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation SummitDecember 1, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 20, 2023 | thetimes.co.ukSkye McAlpine’s easy one-tray dinner recipesNovember 10, 2023 | mirror.co.ukMatthew Perry's ex co-star Ione Skye shares heartbreaking last texts with Friends actorNovember 8, 2023 | morningstar.comSkye Bioscience Inc Ordinary Shares SKYEOctober 26, 2023 | msn.comSkye Bioscience posts early-stage data for glaucoma therapyOctober 25, 2023 | finance.yahoo.comSkye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of GlaucomaDecember 1, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.October 20, 2023 | finance.yahoo.comCORRECTION: Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"October 10, 2023 | thetimes.co.ukSkye McAlpine’s cakes with carrot, sweet potato and pumpkinOctober 1, 2023 | bbc.comHeritage award for 89-year-old Skye ferry crossingSeptember 27, 2023 | finance.yahoo.comSkye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a TrialSeptember 5, 2023 | finance.yahoo.comSkye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment ConferenceAugust 14, 2023 | finance.yahoo.comSkye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual ConferenceJuly 13, 2023 | finance.yahoo.comSkye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic EmulsionJuly 6, 2023 | msn.comSkye Completes Production Of Cannabinoid Based Drug In Preparation For Glaucoma Clinical TrialJune 9, 2023 | travel.usnews.comIsle of SkyeJune 5, 2023 | finance.yahoo.comSkye Bioscience to Present at LD Micro Invitational XIIIMay 15, 2023 | finance.yahoo.comSkye Bioscience Receives Positive Safety Review in First Multiple-Administration Cohort of Phase 1 Study of SBI-100 Ophthalmic EmulsionApril 29, 2023 | finance.yahoo.comSkye Bioscience, Inc. (SKYE) Stock Historical Prices & Data - Yahoo FinanceApril 27, 2023 | finance.yahoo.comSkye Bioscience Begins Dosing Phase 1 Fourth Cohort in Clinical Trial of Novel CB1R AgonistApril 19, 2023 | msn.comShort Volatility Alert: Skye BioscienceApril 4, 2023 | finanznachrichten.deSkye Bioscience, Inc.: Skye Bioscience Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic EmulsionApril 4, 2023 | finance.yahoo.comSkye Bioscience Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic EmulsionApril 3, 2023 | finanznachrichten.deSkye Bioscience, Inc.: Skye Bioscience's Novel Cannabinoid Derivative Reduces Pain in Animal Model; Results Published in Scientific JournalMarch 15, 2023 | msn.comEthics Committee Approves Starting Multiple Ascending Dose Arm Of Phase 1 Study Of Cannabinoid Based Drug For Treatment Of GlaucomaSee More Headlines Receive SKYE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today12/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:SKYE CUSIPN/A CIK1516551 Webskyebioscience.com Phone(858) 410-0266FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($10.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,480,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-546.87% Debt Debt-to-Equity RatioN/A Current Ratio1.11 Quick Ratio1.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book3.93Miscellaneous Outstanding Shares3,890,000Free Float3,858,000Market Cap$6.73 million OptionableNot Optionable Beta0.91 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Punit S. Dhillon B.A. (Age 43)Executive Chairman, President, CEO & Secretary Comp: $733.08kMs. Kaitlyn Melanie Arsenault CPA (Age 36)Chief Financial Officer Comp: $455.89kDr. Christopher G. Twitty Ph.D. (Age 50)Chief Scientific Officer Mr. Tu Diep M.Sc.Chief Development OfficerKey CompetitorsCingulateNASDAQ:CINGChemomab TherapeuticsNASDAQ:CMMBBiofronteraNASDAQ:BFRIBio-PathNASDAQ:BPTHRezoluteOTCMKTS:RZLTDView All Competitors SKYE Stock Analysis - Frequently Asked Questions How have SKYE shares performed in 2023? Skye Bioscience's stock was trading at $0.0162 at the beginning of 2023. Since then, SKYE shares have increased by 10,579.0% and is now trading at $1.73. View the best growth stocks for 2023 here. Are investors shorting Skye Bioscience? Skye Bioscience saw a drop in short interest in October. As of October 31st, there was short interest totaling 100 shares, a drop of 66.7% from the October 15th total of 300 shares. Based on an average daily volume of 7,100 shares, the days-to-cover ratio is presently 0.0 days. View Skye Bioscience's Short Interest. How were Skye Bioscience's earnings last quarter? Skye Bioscience, Inc. (OTCMKTS:SKYE) announced its earnings results on Monday, November, 13th. The company reported ($3.17) earnings per share (EPS) for the quarter. How do I buy shares of Skye Bioscience? Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTCMKTS:SKYE) was last updated on 12/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.